Insider · CIK 0001480111

Doberstein Stephen K

Reports to the SEC for 3 companies · DALLAS, TX

sec.gov

Transactions

Companies

Filings

CIK

0001480111

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-08-27	FBRXForte Biosciences, Inc. · Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−1,000 sh	—	—	0
2026-08-27	FBRXForte Biosciences, Inc. · Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−31K sh	—	—	0
2026-08-27	FBRXForte Biosciences, Inc. · Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−2,000 sh	—	—	0
2026-08-27	FBRXForte Biosciences, Inc. · Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−1,000 sh	—	—	0
2026-08-27	FBRXForte Biosciences, Inc. · Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−2,000 sh	—	—	0
2026-08-27	FBRXForte Biosciences, Inc. · Restricted Stock UnitsD Disposition to Issuer	Director	DDisposition to Issuer	−18.4K sh	—	—	0
2026-05-29	FBRXForte Biosciences, Inc. · Restricted Stock UnitsA Award	Director	AAward	+18.4K sh	—	—	18,353
2025-03-20	FBRXForte Biosciences, Inc. · Stock Option (right to buy)A Award	Director	AAward	+31K sh	—	—	31,000
2024-08-20	FBRXForte Biosciences, Inc. · Stock Option (right to buy)A Award	Director	AAward	+50K sh	—	—	50,000
2023-09-19	FBRXForte Biosciences, Inc. · Stock Option (right to buy)A Award	Director	AAward	+25K sh	—	—	25,000
2022-06-01	FBRXForte Biosciences, Inc. · Stock Option (right to buy)A Award	Director	AAward	+25K sh	—	—	25,000
2022-05-12	FBRXForte Biosciences, Inc. · Stock Option (right to buy)A Award	Director	AAward	+50K sh	—	—	50,000
2021-12-28	Dicerna Pharmaceuticals IncDirector Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−15K sh	—	—	0
2021-12-28	Dicerna Pharmaceuticals IncDirector Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−15K sh	—	—	0
2021-12-28	Dicerna Pharmaceuticals IncDirector Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−25K sh	—	—	0
2021-12-28	Dicerna Pharmaceuticals IncRestricted Stock UnitsD Disposition to Issuer	Director	DDisposition to Issuer	−3,333 sh	—	—	0
2021-12-28	Dicerna Pharmaceuticals IncU Disposition from Tender	Director	UDisposition from Tender	−3,333 sh	$38.25	−$127K	0
2021-06-03	Dicerna Pharmaceuticals IncRestricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−3,333 sh	—	—	0
2021-06-03	Dicerna Pharmaceuticals IncDirector Stock Option (Right to Buy)A Award	Director	AAward	+15K sh	—	—	15,000
2021-06-03	Dicerna Pharmaceuticals IncRestricted Stock UnitsA Award	Director	AAward	+3,333 sh	—	—	3,333
2021-06-03	Dicerna Pharmaceuticals IncM Exercise/Conversion	Director	MExercise/Conversion	+3,333 sh	—	—	3,333
2020-06-15	Dicerna Pharmaceuticals IncDirector Stock Option (Right to Buy)A Award	Director	AAward	+15K sh	—	—	15,000
2020-06-15	Dicerna Pharmaceuticals IncRestricted Stock UnitsA Award	Director	AAward	+3,333 sh	—	—	3,333
2020-03-12	Dicerna Pharmaceuticals IncDirector Stock Option (Right to Buy)A Award	Director	AAward	+25K sh	—	—	25,000
2019-09-05	NKTRNEKTAR THERAPEUTICSP Purchase	SVP & Chief Scientific Officer	PPurchase	+15K sh	$17.28	+$259K	107,668
2019-08-16	NKTRNEKTAR THERAPEUTICSS Sale	SVP & Chief Scientific Officer	SSale	−3,245 sh	$18.15	−$58.9K	92,668
2019-05-16	NKTRNEKTAR THERAPEUTICSS Sale	SVP & Chief Scientific Officer	SSale	−3,461 sh	$31.37	−$109K	95,913
2019-02-19	NKTRNEKTAR THERAPEUTICSS Sale	SVP & Chief Scientific Officer	SSale	−3,310 sh	$42.39	−$140K	99,374
2018-12-14	NKTRNEKTAR THERAPEUTICS · Stock OptionA Award	SVP & Chief Scientific Officer	AAward	+48.4K sh	—	—	48,400
2018-12-14	NKTRNEKTAR THERAPEUTICSA Award	SVP & Chief Scientific Officer	AAward	+24K sh	—	—	102,684
2018-11-16	NKTRNEKTAR THERAPEUTICSS Sale	SVP & Chief Scientific Officer	SSale	−4,524 sh	$38.25	−$173K	78,734
2018-08-16	NKTRNEKTAR THERAPEUTICSD Disposition to Issuer	SVP & Chief Scientific Officer	DDisposition to Issuer	−6,701 sh	$58.40	−$391K	83,258
2018-08-15	NKTRNEKTAR THERAPEUTICS · Stock OptionA Award	SVP & Chief Scientific Officer	AAward	+65K sh	—	—	65,000
2018-08-15	NKTRNEKTAR THERAPEUTICSA Award	SVP & Chief Scientific Officer	AAward	+26K sh	—	—	89,959
2018-05-16	NKTRNEKTAR THERAPEUTICSS Sale	SVP & Chief Scientific Officer	SSale	−3,435 sh	$83.39	−$286K	63,959
2018-04-09	NKTRNEKTAR THERAPEUTICSS Sale	SVP & Chief Scientific Officer	SSale	−49.5K sh	$96.13	−$4.76M	67,394
2018-04-09	NKTRNEKTAR THERAPEUTICS · Stock OptionM Exercise/Conversion	SVP & Chief Scientific Officer	MExercise/Conversion	−49.5K sh	—	—	0
2018-04-09	NKTRNEKTAR THERAPEUTICSM Exercise/Conversion	SVP & Chief Scientific Officer	MExercise/Conversion	+49.5K sh	$7.21	+$357K	116,894
2018-04-06	NKTRNEKTAR THERAPEUTICSM Exercise/Conversion	SVP & Chief Scientific Officer	MExercise/Conversion	+500 sh	$7.21	+$3,605	177,894
2018-04-06	NKTRNEKTAR THERAPEUTICSS Sale	SVP & Chief Scientific Officer	SSale	−111K sh	$91.69	−$10.1M	67,394
2018-04-06	NKTRNEKTAR THERAPEUTICSM Exercise/Conversion	SVP & Chief Scientific Officer	MExercise/Conversion	+50K sh	$7.21	+$361K	177,394
2018-04-06	NKTRNEKTAR THERAPEUTICS · Stock OptionM Exercise/Conversion	SVP & Chief Scientific Officer	MExercise/Conversion	−500 sh	—	—	49,500
2018-04-06	NKTRNEKTAR THERAPEUTICSM Exercise/Conversion	SVP & Chief Scientific Officer	MExercise/Conversion	+60K sh	$10.69	+$641K	127,394
2018-04-06	NKTRNEKTAR THERAPEUTICS · Stock OptionM Exercise/Conversion	SVP & Chief Scientific Officer	MExercise/Conversion	−50K sh	—	—	0
2018-04-06	NKTRNEKTAR THERAPEUTICS · Stock OptionM Exercise/Conversion	SVP & Chief Scientific Officer	MExercise/Conversion	−60K sh	—	—	0
2018-02-16	NKTRNEKTAR THERAPEUTICSS Sale	SVP & Chief Scientific Officer	SSale	−2,426 sh	$82.94	−$201K	67,394
2017-12-15	NKTRNEKTAR THERAPEUTICSA Award	SVP & Chief Scientific Officer	AAward	+26K sh	—	—	69,820
2017-12-15	NKTRNEKTAR THERAPEUTICS · Stock OptionA Award	SVP & Chief Scientific Officer	AAward	+65K sh	—	—	65,000
2017-11-16	NKTRNEKTAR THERAPEUTICSD Disposition to Issuer	SVP & Chief Scientific Officer	DDisposition to Issuer	−4,782 sh	$44.23	−$212K	43,820
2017-11-15	NKTRNEKTAR THERAPEUTICSA Award	SVP & Chief Scientific Officer	AAward	+17.5K sh	—	—	48,602

Recent filings

Accepted (ET)
Aug 274
Doberstein Stephen K0001480111-26-000003
SEC(opens sec.gov)
Jun 24
Doberstein Stephen K0001480111-26-000002
SEC(opens sec.gov)
Mar 214
Doberstein Stephen K0001415889-25-008782
SEC(opens sec.gov)
Aug 224
Doberstein Stephen K0001415889-24-022002
SEC(opens sec.gov)
Sep 204
Doberstein Stephen K0001209191-23-050190
SEC(opens sec.gov)
Jun 24
Doberstein Stephen K0001209191-22-033612
SEC(opens sec.gov)
May 164
Doberstein Stephen K0001209191-22-029225
SEC(opens sec.gov)
Dec 294
Doberstein Stephen K0001399529-21-000197
SEC(opens sec.gov)
Jun 74
Doberstein Stephen K0001399529-21-000104
SEC(opens sec.gov)

Companies

Address

C/O FORTE BIOSCIENCES, INC. 3060 PEGASUS PARK DR., BLDG 6

DALLAS, TX, 75247